By Adam Lidgett ( December 1, 2020, 9:47 PM EST) -- A biosimilars and generic-drug industry trade group has urged federal lawmakers to set their sights on measures to ensure that patients can more easily get their hands on biosimilars, rein in allegedly anti-competitive conduct related to brand-name medicines and make updates to Medicare Part D. ...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.